Berlin, Germany

Ludwig Nuesslein

This inventor holds 1 USPTO granted patent. Top assignee: Schering Aktiengesellschaft. Active years: 1983.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ludwig Nuesslein: Innovator in Antifungal Compounds

Introduction

Ludwig Nuesslein is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of antifungal compounds, particularly through his innovative work on 1,3,4-thiadiazole derivatives. His research has led to advancements in the production of novel antifungal agents.

Latest Patents

Nuesslein holds a patent for "Fungicidal 2-sulfinyl-5-sulfonyl-1,3,4-thiadiazole derivatives." This patent describes a method for producing antifungal 1,3,4-thiadiazole derivatives characterized by a specific general formula. The compounds are created by reacting 1,3,4-thiadiazole derivatives with a compound of the general formula R₁-SH, which are then oxidized using an organic or inorganic oxidant. This innovative approach has the potential to enhance the efficacy of antifungal treatments.

Career Highlights

Throughout his career, Ludwig Nuesslein has been associated with Schering Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work has focused on developing effective antifungal solutions, contributing to the advancement of medical treatments.

Collaborations

Nuesslein has collaborated with esteemed colleagues such as Dietrich Baumert and Ernst A Pieroh. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of antifungal research.

Conclusion

Ludwig Nuesslein's contributions to the development of antifungal compounds highlight his role as an important inventor in the pharmaceutical industry. His innovative patent and collaborations with other professionals underscore the significance of his work in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…